Genetic Technologies Ltd (GENE) Quote

Fascinating how quiet this board is...people do realize less than 3 million OS,right?....This puppy will pop at some point...Imagine if 400-800k or more shares get bought up

Took a position

What leaked?

GENE 10Q 2/27

GENE under $2

GENE new 52 week low

Gene is now junk! Sold out this turd for end of year loss. Going nowhere but back under 1$

GENE new 52 week low

Maybe shorts going to cover before split

They are going to make a 60 cent stock 60$ seems a little crazy

I hope so

Almost time for this to double

Somebody buy this company this is pathetic, but I did buy more today

Its going to be the next bio dynasty! $$$$$

NP man. This one is a starving wolf with flees. Smells bad too!

GENE: Admiral Subs, Orion Fleet Commander!! (SORRY for my belated replies here, but off today behind family matters; but MONSTER THANKS!! Will still toss bucks at some of your picks today, when they lock-in for launch or set-back.)

This company is the next merck! Enough said, buy em up now an wait it out. We loaded here an still adding

News #2 GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.

Highlights:

Results from the trial are expected to change the way risk is assessed and reshape the standard of care in general practice for serious disease.
The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
Results of this study could lead to a revision of national guidelines and improve risk stratification for four of the most common cancers in Australia; breast, colorectal, prostate, and melanoma.
The study will recruit nearly 600 participants from eight general practices across Victoria.
As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.
The project titled, “The CASSOWARY (CAncer genomic riSk ScOres in primARY Care) Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice”. This is a multi-institutional, multidisciplinary collaborative initiative with internationally recognised experts. Disciplines include academic, general practice and primary care trials, clinical genetics and genetic counselling, genetic/cancer epidemiology, health economics and modelling, biostatistics, implementation science, genomic test development and commercialisation, consumer investigators with lived experience of cancer and associate investigators with expertise in cancer policy with Cancer Australia. The Cassowary Trial is a collaboration between international investigators from GTG (Industry partner), University of Melbourne and Queen Mary University of London, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, and the Daffodil Centre.

The study will recruit a targeted cohort to create high quality evidence about the clinical utility and cost-effectiveness of using cancer polygenic risk scores, such as geneType multi-Test to tailor cancer screening and possible treatment in general practice.

Professor Jon Emery, the lead investigator of this study team, has an established history in genomics in Australian general practice and has been involved in national and international screening and cancer risk assessment guidelines. This funding is one of several trials that he leads, “We look forward to extending our work in the space of polygenic risk score implementation in general practice. Over the years, our team has created a framework for risk-assessment implementation in clinical practice, and with each subsequent study we are building our evidence to support a structured, real-world implementation strategy.”

This multi-year utility trial will focus on the implementation of four of geneType’s multi-Test integrated polygenic risk scores: breast, colorectal, prostate, and melanoma. The trial will assess patient and provider behaviour, and assess the economic impact of the resulting behaviour.

GTG’s Director of Scientific Affairs, Erika Spaeth, a co-investigator of the study said, “We are proud of our academic partnerships and honoured to be a part of the growing body of evidence showing the utility of polygenic risk in clinical care. We look forward to the implementation evidence outcomes that will result from this utility study.”

GTG has a strong history of research partnerships with academic institutions, including the University of Melbourne. The company is committed to its collaborative initiatives that support the evolution of predictive population healthcare. GTG’s CEO, Simon Morriss noted, “This is an important step forward for preventive precision medicine. The results from the Cassowary Trial have the ability to support the clinical utility of geneType multi-Test and even more importantly provide compelling evidence for its’ inclusion into National Guidelines and standard of care. The results from this study will be a major leap forward for geneType.”

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare

MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessible for order in Australia, marking a significant milestone in the journey to redefine preventative healthcare.

Early 2023, GTG unveiled the tests in the United States, introducing three additional diseases to the already remarkable geneType Multi-Risk Test platform. Today, with immense pride, we share the news that these innovations, including assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, have been authorized for sale in Australia by National Association of Testing Authority (NATA). This expanded genetic test now offers a comprehensive evaluation of risk for a total of nine individual serious diseases, all extracted from a single, simple saliva sample.

The risk assessment panel revolves around Oncology, Cardiovascular, and Metabolic diseases, covering:

Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Melanoma
Colorectal Cancer
Diabetes
Coronary Artery Disease
Atrial Fibrillation
The approval granted by NATA follows the release in March by the Centers for Medicare & Medicaid (CMS) to offer the enhanced panel in the United States.

The expanded Multi-test panel caters to individuals of diverse ethnic backgrounds, focusing on those over the age of 30. Each of these newly incorporated diseases holds a significant threat to public health, with dire statistics calling for immediate attention.

According to the Australian Institute of Health and Welfare, 2023 is expected to witness approximately 10,639 new cases of melanoma, Australia's third most diagnosed cancer. Pancreatic cancer estimates are even grimmer, projecting 2,355 new diagnoses in 2023, with a staggering 87% mortality rate. Early identification of high-risk individuals for both melanoma and pancreatic cancer offers a vital window for early intervention, potentially saving countless lives.

In the case of atrial fibrillation (AFib), research indicates its impact on approximately 2% of the Australian population, equating to over 500,000 individuals. Detecting AFib early can pave the way for interventions that improve patient outcomes, extend life expectancy, and save lives.

Simon Morriss, CEO of GTG, states, "Securing approval for the expanded version of the Multi-test in Australia underscores GTG's unwavering dedication to lead the world in delivering personalized risk assessments, thereby enabling population wide preventative healthcare for a range of serious diseases."

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

https://www.globenewswire.com/newsroom/ti?nf=ODkxOTY4MyM1ODA3MzA2IzIwNTAwMzg=
https://ml.globenewswire.com/media/OGNiZWVkYTQtMzlkYy00ZjIwLTlmNjEtYjE3OTUyODM4YjgyLTEwNjE2MDk=/tiny/Genetic-Technologies-Ltd.png

Source: Genetic Technologies Ltd
© 2023 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings

Harry I hope you right this company should be bought out by Merck or someone with big cancer portfolio

5$ coming, load now, going to go up

Breakout coming

GENE new 52 week low

Watching this for a big jump

I watched the clip on Balancing Act about breast Cancer and "Gene Type". Very good news.

Advertising starting only up from here

They where going to start selling campaign in us in may will see

Stock should be 5 to 10$ by now. Sell company to highest bidder

This is going to pop big one of these days

Have to read up on seeing alpha web site the meeting it’s typed up. Big things planned for marketing in USA. Big meeting in Montreal Canada in May. Buy your shares now and watch. Nice after hours movement

Pfizer in talks to buy seagen 30 billion for cancer drugs market too big not to buy gene

This ticker could be a huge winner! $$$$
The science is looking very promising

Moderna in with life edit for gene manipulation matter of til phizer buys this beauty

Added an holding here

Not giving financial advice though, right?

Hold hold add add

Phizer or Merck oncology division will buy this out more diagnoses more money they make on chemotherapy. Big boys holding it down I go my shares for the ride

Open up that report in new section shows there new path of advertisement and stuff with patents in countries

3$

Let’s see 4 to 6$ today folks big buys and pr blitzing occurring

I forgot it was also a ticker going across the screen on mad money last night

Share outstanding I have 19 million does not seem like a lot with volume this week

Will see the bump at 830

These test are usually 2500$ each maybe some don’t know how much money this company is going to make worldwide with new results from Harvard will be a game changer

This thing could really pop tomorrow, should be very active an agree huge volume may happen

Bring on the volume!

Current buys are people who can buy after hours

200 million share day tomorrow

Hope it continues higher tomorrow AM

Off to the races again